Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
Status:
Unknown status
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This is a phase 2b, randomized, open-label, prospective, multicenter study comparing
treatment with INNO 206 to doxorubicin in subjects with metastatic, locally advanced, or
unresectable soft tissue sarcomas who have not been previously treated with any chemotherapy
except potentially as adjuvant or neoadjuvant chemotherapy, and no evidence of tumor
recurrence has occurred for at least 12 months.